Literature DB >> 11393785

Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.

G van der Pluijm1, B Sijmons, H Vloedgraven, M Deckers, S Papapoulos, C Löwik.   

Abstract

Tumor-stroma interactions are of primary importance in determining the pathogenesis of metastasis. Here, we describe the application of sensitive competitive polymerase chain reaction (PCR) techniques for detection and quantitation of human breast cancer cells (MDA-MB-231) in an in vivo mouse model of experimental metastasis. Human-specific oligonucleotide primers in competitive PCR reactions were used to quantify the amount of MDA-MB-231 cells per tissue per organ. Using this species-specific (semi)quantitative PCR approach, gene expression patterns of (human) tumor cells or (mouse) stromal cells in metastatic lesions in the skeleton or soft tissues were investigated and compared. In all metastatic lesions, MDA-MB-231 cells express angiogenic factors (vascular endothelial growth factors [VEGFs]; VEGF-A, -B, and -C) and bone-acting cytokines (parathyroid hormone-related protein [PTHrP] and macrophage colony-stimulating factor [M-CSF]). In these metastases, PECAM-1-positive blood vessels and stromal cells of mouse origin are detected. The latter express angiogenic factors and markers of sprouting vessels (VEGF receptors flt-1/flk - 1/flk-4 and CD31/PECAM-1). Strikingly, steady-state messenger RNA (mRNA) levels of VEGF-A and -B and the major bone resorption stimulators PTHrP and M-CSF by tumor cells were elevated significantly in bone versus soft tissues (p < or = 0.05, p < or = 0.0001, p < or = 0.001, and p < or = 0.05, respectively), indicating tissue-specific expression of these tumor progression factors. In conclusion, MDA-MB-231 breast cancer cells express a variety of factors in vivo that have been implicated in metastatic bone disease and that correlate with poor survival of patients with breast cancer. We hypothesize that the observed up-regulated expression of angiogenic and bone-resorbing factors by the breast cancer cells in the skeleton underlie the clinically observed osteotropism of breast cancer cells and pathogenesis of osteolytic bone metastases. The application of the species-specific competitive PCR-based assay in vivo can provide new information concerning the involvement of gene families in tumor progression and metastatic disease and greatly facilitates the study of tumor-stroma interactions in cancer invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393785     DOI: 10.1359/jbmr.2001.16.6.1077

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  35 in total

1.  Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

Authors:  G van der Pluijm; B Sijmons; H Vloedgraven; C van der Bent; J W Drijfhout; J Verheijen; P Quax; M Karperien; S Papapoulos; C Löwik
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

Review 2.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Stephanie Corn; Abraham Schneider; Laurie K McCauley
Journal:  Cancer Treat Res       Date:  2004

3.  Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

Authors:  Ruth Schwaninger; Cyrill A Rentsch; Antoinette Wetterwald; Geertje van der Horst; Rutger L van Bezooijen; Gabri van der Pluijm; Clemens W G M Löwik; Karin Ackermann; Walter Pyerin; Freddie C Hamdy; George N Thalmann; Marco G Cecchini
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

4.  Transforming growth factor-β in stem cells and tissue homeostasis.

Authors:  Xin Xu; Liwei Zheng; Quan Yuan; Gehua Zhen; Janet L Crane; Xuedong Zhou; Xu Cao
Journal:  Bone Res       Date:  2018-01-31       Impact factor: 13.567

5.  Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo.

Authors:  Wolfgang E Gallwitz; Theresa A Guise; Gregory R Mundy
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

6.  Alterations of microvascular density in bone metastases of adenocarcinomas.

Authors:  Tamás Lôrincz; József Tímár; Miklós Szendrôi
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

Review 7.  Bone metabolism and new targets for intervention.

Authors:  Bulent Akduman; E David Crawford
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

8.  Orthopaedic perspective on bone metastasis.

Authors:  Alan P Molloy; Gary C O'Toole
Journal:  World J Orthop       Date:  2013-07-18

9.  Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.

Authors:  Tobias Bäuerle; Heidegard Hilbig; Sönke Bartling; Fabian Kiessling; Astrid Kersten; Annette Schmitt-Gräff; Hans-Ulrich Kauczor; Stefan Delorme; Martin R Berger
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

10.  BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.

Authors:  Jeroen T Buijs; Cyrill A Rentsch; Geertje van der Horst; Petra G M van Overveld; Antoinette Wetterwald; Ruth Schwaninger; Niek V Henriquez; Peter Ten Dijke; Fran Borovecki; Regula Markwalder; George N Thalmann; Socrates E Papapoulos; Rob C M Pelger; Slobodan Vukicevic; Marco G Cecchini; Clemens W G M Löwik; Gabri van der Pluijm
Journal:  Am J Pathol       Date:  2007-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.